Clarametyx Biosciences is pioneering a novel approach to combat life-threatening bacterial infections, particularly those associated with biofilms. Their primary technology platform focuses on developing immune-enabling biologic therapies, such as CMTX-101, which is designed to target and dismantle the protective biofilm structures that bacteria form. By disrupting these biofilms, Clarametyx aims to enhance the effectiveness of existing antibiotics and the body's immune response, thereby improving patient outcomes and potentially reducing the duration and dosage of antibiotic treatments. This innovative strategy not only addresses active infections but also seeks to prevent the formation of biofilms, which are often responsible for chronic infections.

The company has garnered recognition for its advancements in the field, including being awarded "Infectious Disease Innovation of the Year" at the 2024 BioTech Breakthrough Awards. Clarametyx's technology is particularly significant as it targets a universal component of biofilm structures, making it applicable across various bacterial infections. This approach is crucial in the fight against antimicrobial resistance, a growing public health concern, as it aims to optimize antibiotic use and support antimicrobial stewardship. With a focus on challenging respiratory infections, Clarametyx is actively advancing its pipeline of therapies and vaccines to address persistent and difficult-to-treat infections.

United States

Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.

Clarametyx Biosciences

Company Details